Cargando…

Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic

Despite the progress in the management of COVID-19, effective oral antiviral agents are still lacking. In the present review, the potential beneficial effects of molnupiravir in the management of COVID-19 are discussed. A literature search in Google Scholar, Scopus, PubMed and clinicaltrials.gov for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khiali, Sajad, Khani, Elnaz, B Rouy, Samineh, Entezari-Maleki, Taher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961474/ https://www.ncbi.nlm.nih.gov/pubmed/35199608 http://dx.doi.org/10.2217/fmb-2021-0252

Ejemplares similares

Potential pharmacologic treatments for COVID-19 smell and taste loss: A comprehensive review
por: Khani, Elnaz, et al.
Publicado: (2021)

Anticoagulation in COVID-19: DDI Perspective
por: Khiali, Sajad, et al.
Publicado: (2020)

Tocilizumab in COVID-19 management: addressing time of starting treatment
por: Khiali, Sajad, et al.
Publicado: (2023)

Isotretinoin; A review on the Utilization Pattern in Pregnancy
por: Khiali, Sajad, et al.
Publicado: (2018)

SARS-CoV-2 and probable lung cancer risk
por: Khiali, Sajad, et al.
Publicado: (2022)

Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis
por: Rezagholizadeh, Afra, et al.
Publicado: (2021)

A commentary on “Unexpected sudden rise of human monkeypox cases in multiple non-endemic countries amid COVID-19 pandemic and salient counteracting strategies: Another potential global threat?” (Int J Surg 2022;103:106705)
por: Khani, Elnaz, et al.
Publicado: (2022)

Fluvoxamine and long COVID-19; a new role for sigma-1 receptor (S1R) agonists
por: Khani, Elnaz, et al.
Publicado: (2022)

Commentary on ‘Implications of the SARS-CoV-2 subvariants BA.4 and BA.5’
por: Khani, Elnaz, et al.
Publicado: (2023)

Antiviral Efficacy of Molnupiravir for COVID-19 Treatment
por: Bai, Yuan, et al.
Publicado: (2022)

Empagliflozin and colchicine in patients with reduced left ventricular ejection fraction following ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: a study protocol for a randomized, double-blinded, three-arm parallel-group, controlled trial
por: Khiali, Sajad, et al.
Publicado: (2023)

Molnupiravir and Its Antiviral Activity Against COVID-19
por: Tian, Lili, et al.
Publicado: (2022)

Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity
por: Yip, Ashley Jia Wen, et al.
Publicado: (2022)

Review on molnupiravir as a promising oral drug for the treatment of COVID-19
por: Zarenezhad, Elham, et al.
Publicado: (2022)

Antiviral activity of molnupiravir against COVID-19: a schematic review of evidences
por: Singla, Shivali, et al.
Publicado: (2022)

On the choice of Molnupiravir and Paxlovid as the only antivirals permitted for COVID-19 infection in Australia
por: Boretti, Alberto
Publicado: (2023)

Molnupiravir for COVID-19
Publicado: (2022)

Engineered Ribosyl-1-Kinase Enables Concise Synthesis of Molnupiravir, an Antiviral for COVID-19
por: McIntosh, John A., et al.
Publicado: (2021)

An Engineered Cytidine Deaminase for Biocatalytic Production of a Key Intermediate of the Covid-19 Antiviral Molnupiravir
por: Burke, Ashleigh J., et al.
Publicado: (2022)

Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19
por: Painter, George R, et al.
Publicado: (2021)

A metabolic modeling approach reveals promising therapeutic targets and antiviral drugs to combat COVID-19
por: Santos-Beneit, Fernando, et al.
Publicado: (2021)

Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir
por: Parums, Dinah V.
Publicado: (2022)

Enoxaparin’s potential mechanisms against SARS-CoV-2
por: Afsharirad, Bentelhoda, et al.
Publicado: (2023)

Molnupiravir: First Approval
por: Syed, Yahiya Y.
Publicado: (2022)

Computational Analysis of Molnupiravir
por: Sharov, Artem V., et al.
Publicado: (2022)

Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses
por: Wang, Yining, et al.
Publicado: (2021)

Nudix hydrolase 18 catalyzes the hydrolysis of active triphosphate metabolites of the antivirals remdesivir, ribavirin, and molnupiravir
por: Jemth, Ann-Sofie, et al.
Publicado: (2022)

Efficacy and safety of molnupiravir for COVID-19 patients
por: Fatima, Maurish, et al.
Publicado: (2022)

A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval
por: Ashour, Nada A, et al.
Publicado: (2022)

Advancements of Nanotechnology and Nanomaterials in Environmental and Human Protection for Combatting the COVID-19 During and Post-pandemic Era: A Comprehensive Scientific Review
por: Wibowo, Yudha Gusti, et al.
Publicado: (2023)

Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis
por: Wen, Wen, et al.
Publicado: (2022)

Toward a Practical, Nonenzymatic Process for Investigational COVID-19 Antiviral Molnupiravir from Cytidine: Supply-Centered Synthesis
por: Gopalsamuthiram, Vijayagopal, et al.
Publicado: (2021)

Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial
por: Zou, Rongrong, et al.
Publicado: (2022)

Immunosuppressants exert differential effects on pan‐coronavirus infection and distinct combinatory antiviral activity with molnupiravir and nirmatrelvir
por: Wang, Yining, et al.
Publicado: (2023)

Antiviral monoclonal antibody cocktails as a modern weapon in combating pandemics
por: Liu, Dingjiang, et al.
Publicado: (2021)

Molnupiravir in COVID-19: A systematic review of literature
por: Singh, Awadhesh Kumar, et al.
Publicado: (2021)

What will be the role of molnupiravir in the treatment of COVID-19 infection?
por: Vitiello, Antonio, et al.
Publicado: (2021)

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
por: Jayk Bernal, Angélica, et al.
Publicado: (2021)

Molnupiravir: A new candidate for COVID‐19 treatment
por: Pourkarim, Fariba, et al.
Publicado: (2021)

Vascularite rétinienne post-Covid-19 et Molnupiravir
por: Lassouli, I., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ght7hu1i6tt376su05l0lko92l